JP6987271B2 - 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 - Google Patents

新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 Download PDF

Info

Publication number
JP6987271B2
JP6987271B2 JP2020552072A JP2020552072A JP6987271B2 JP 6987271 B2 JP6987271 B2 JP 6987271B2 JP 2020552072 A JP2020552072 A JP 2020552072A JP 2020552072 A JP2020552072 A JP 2020552072A JP 6987271 B2 JP6987271 B2 JP 6987271B2
Authority
JP
Japan
Prior art keywords
disease
syndrome
ifn
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020552072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505691A5 (enExample
JP2021505691A (ja
Inventor
ボー ファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chon Therapeutics Inc Ltd
Original Assignee
Chon Therapeutics Inc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chon Therapeutics Inc Ltd filed Critical Chon Therapeutics Inc Ltd
Publication of JP2021505691A publication Critical patent/JP2021505691A/ja
Publication of JP2021505691A5 publication Critical patent/JP2021505691A5/ja
Application granted granted Critical
Publication of JP6987271B2 publication Critical patent/JP6987271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/30—Quinones containing groups having oxygen atoms singly bound to carbon atoms with polycyclic non-condensed quinoid structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020552072A 2017-12-11 2018-02-02 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 Active JP6987271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711309136.0 2017-12-11
CN201711309136.0A CN109985030B (zh) 2017-12-11 2017-12-11 醌式查尔酮化合物在制备抗肿瘤药物中的应用
PCT/CN2018/075163 WO2019114125A1 (en) 2017-12-11 2018-02-02 A novel quinochalcone compound and uses thereof for treating cancer or inflammation

Publications (3)

Publication Number Publication Date
JP2021505691A JP2021505691A (ja) 2021-02-18
JP2021505691A5 JP2021505691A5 (enExample) 2021-04-01
JP6987271B2 true JP6987271B2 (ja) 2021-12-22

Family

ID=66819884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552072A Active JP6987271B2 (ja) 2017-12-11 2018-02-02 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途

Country Status (6)

Country Link
US (1) US10988429B2 (enExample)
EP (1) EP3675841B1 (enExample)
JP (1) JP6987271B2 (enExample)
CN (1) CN109985030B (enExample)
ES (1) ES2979333T3 (enExample)
WO (1) WO2019114125A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409522B (zh) * 2022-03-01 2023-08-15 贵州省天然产物研究中心 一种查尔酮衍生物及其制备方法与用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054998A1 (ko) * 2011-10-13 2013-04-18 건국대학교 산학협력단 신규한 칼콘 유도체 및 이를 유효성분으로 하는 항암제 조성물
CN105085218B (zh) * 2014-05-22 2019-04-09 中国医学科学院药物研究所 一类a环具有甲基的醌式查尔酮化合物，制法与抗炎活性
CN105085219B (zh) * 2014-05-22 2019-04-09 中国医学科学院药物研究所 A环具有异戊烯基的醌式查尔酮化合物，制法与抗炎活性

Also Published As

Publication number Publication date
CN109985030B (zh) 2021-07-06
EP3675841C0 (en) 2024-04-10
EP3675841A4 (en) 2021-06-09
US10988429B2 (en) 2021-04-27
ES2979333T3 (es) 2024-09-25
JP2021505691A (ja) 2021-02-18
EP3675841A1 (en) 2020-07-08
US20200377439A1 (en) 2020-12-03
CN109985030A (zh) 2019-07-09
WO2019114125A1 (en) 2019-06-20
EP3675841B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CN104109193B (zh) 一种抗癌活性肽变体及其应用
US20220249643A1 (en) Anti-neoplastic combined pharmaceutical composition and application thereof
US20220133675A1 (en) Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia
EP4252754A1 (en) Pharmaceutical composition for enhancing cell killing, and use thereof
CN109528731B (zh) 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用
US10988429B2 (en) Quinochalcone compound and uses thereof for treating cancer or inflammation
WO2025207803A1 (en) Lipid compounds, compositions and methods of use thereof
CN117866069B (zh) 一种碘-131标记的小分子多肽tfmp-y4及其制备方法和应用
CN108324952B (zh) 金簇分子的新应用
TW200936166A (en) Pharmaceutical composition and combined agent
US20200093789A1 (en) Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
US11547694B2 (en) CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease
US20200239532A1 (en) Recombinant fusion protein of baf57 and uses thereof
CN118184759B (zh) Atap多肽及其疫苗的制备方法和应用
CN101653608B (zh) 含有肝细胞生长因子受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
WO2019103660A1 (en) Method of multiple sclerosis treatment (variants)
CN121550252A (zh) 双二羧酸二氨络铂抗癌药物
US20100003268A1 (en) Therapy of Malignant Neoplasias
JP2026500734A (ja) 医薬組み合わせ、及びその使用
CN118436642A (zh) 干扰肿瘤Treg细胞分化的药物及其应用
CN114585635A (zh) 作为抗癌症剂的n-酰化组氨酸二肽
CN106699863A (zh) 一种抗癌活性肽变体及其应用
CN106699865A (zh) 一种抗癌活性肽变体及其应用
CN106699864A (zh) 一种抗癌活性肽变体及其应用
CN111732631A (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200617

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211130

R150 Certificate of patent or registration of utility model

Ref document number: 6987271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250